Marimastat | MMP inhibitor

CAS:
 154039-60-8
Catalog Number:
 10-4116

Available Options

Size:PriceQuantity 
5 mg$90.00
25 mg$325.00
Request Quote / Bulk / Custom Size
Product Inquiry

Marimastat (154039-60-8) is an orally bioavailable inhibitor of matrix metalloproteinases (IC50’s: MMP-1 = 5 nM, MMP-2 = 6 nM, MMP-3 = 200 nM, MMP-7 = 20 nM, MMP-8 = 2 nM, MMP-9 = 3 nm, MMP-14 = 1.8 nM).1 It has been used to alter the extracellular matrix of the tumor microenvironment in various liposomal3,4 and nano-platforms5-7 along with other therapeutic agents.

References/Citations:

  1. Whittaker et al. (1999), Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors; Chem. Rev. 99 2735
  2. Zhu et al. (2024), Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway; Cell Rep. 43 114065
  3. Lv et al. (2018), Nanoplatform Assembled from a CD44-Targeted Prodrug and Smart Liposomes for Dual Targeting of Tumor Microenvironment and Cancer Cells; ACS Nano. 12 1519
  4. Lyu et al. (2019), Potent delivery of an MMP inhibitor to the tumor microenvironment with thermosensitive liposomes for the suppression of metastasis and angiogenesis; Signal Transduc. Target Ther. 4 26
  5. Xiao et al. (2018), A drug-delivering-drug strategy for combined treatment of metastatic breast cancer; Nanomedicine 14 2678
  6. Lyu et al. (2019), “Locked” cancer cells are more sensitive to chemotherapy; Bioeng. Transl. Med. 4 e10130
  7. Zhang et al. (2021), Dual Targeting of Cancer Cells and MMPs with Self-Assemble Hybrid Nanoparticles for Combination Therapy in Combating Cancer; Pharmaceutics. 13 1990
154039-60-8, BB-2516, BB-2516 supplier, BB2516, Marimastat, Marimastat supplier, MMP inhibitor
CAS:
154039-60-8
Catalog Number:
10-4116
Activity:
MMP inhibitor
Chemical Names:
(2R,3S)-N-[(2S)-3,3-Dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide
Alternate Name:
BB-2516
Molecular Weight:
331.41
Molecular Formula:

C15H29N3O5

Solubility:
Soluble in DMSO (>25 mg/ml)
Physical Properties:
White solid
Purity:

98% HPLC
NMR: (Conforms)

Storage Temperature:
-20°C
Stability:
Stable for up to 2 years when stored as supplied @ -20°C. Solutions in DMSO may be stored at -20°C for up to 2 months.
Shipping Code:
RT

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Marimastat (154039-60-8) is an orally bioavailable inhibitor of matrix metalloproteinases (IC50’s: MMP-1 = 5 nM, MMP-2 = 6 nM, MMP-3 = 200 nM, MMP-7 = 20 nM, MMP-8 = 2 nM, MMP-9 = 3 nm, MMP-14 = 1.8 nM).1 It has been used to alter the extracellular matrix of the tumor microenvironment in various liposomal3,4 and nano-platforms5-7 along with other therapeutic agents.

References/Citations:

  1. Whittaker et al. (1999), Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors; Chem. Rev. 99 2735
  2. Zhu et al. (2024), Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway; Cell Rep. 43 114065
  3. Lv et al. (2018), Nanoplatform Assembled from a CD44-Targeted Prodrug and Smart Liposomes for Dual Targeting of Tumor Microenvironment and Cancer Cells; ACS Nano. 12 1519
  4. Lyu et al. (2019), Potent delivery of an MMP inhibitor to the tumor microenvironment with thermosensitive liposomes for the suppression of metastasis and angiogenesis; Signal Transduc. Target Ther. 4 26
  5. Xiao et al. (2018), A drug-delivering-drug strategy for combined treatment of metastatic breast cancer; Nanomedicine 14 2678
  6. Lyu et al. (2019), “Locked” cancer cells are more sensitive to chemotherapy; Bioeng. Transl. Med. 4 e10130
  7. Zhang et al. (2021), Dual Targeting of Cancer Cells and MMPs with Self-Assemble Hybrid Nanoparticles for Combination Therapy in Combating Cancer; Pharmaceutics. 13 1990

STEM CELL

BOGO